<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063541</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT-U_V2.2_20_Feb_2017</org_study_id>
    <secondary_id>2017-000514-35</secondary_id>
    <nct_id>NCT03063541</nct_id>
  </id_info>
  <brief_title>Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms</brief_title>
  <acronym>PROTECT-U</acronym>
  <official_title>Prospective Randomized Open-label Trial to Evaluate Risk faCTor Management in Patients With Unruptured Intracranial Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schwiete Stiftung, Mannheim, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to assess the hypothesis that a strategy with acetylsalicylic acid
      (ASA) 100 mg/day, intensive blood pressure treatment (targeted systolic blood pressure below
      120 mmHg), and a blood pressure measuring device reduces the risk of aneurysm rupture or
      growth compared with standard care (i.e. no ASA, blood pressure management according to
      standard blood pressure management, no blood pressure measuring device)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>controlled open trial, randomized 1:1</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>observer blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>aneurysm rupture or growth</measure>
    <time_frame>36 months</time_frame>
    <description>aneurysm rupture (i.e. aneurysmal subarachnoid hemorrhage, SAH) or growth (increase in any aneurysm diameter by ≥1mm) on serial imaging (either two MR or CT angiographies)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aneurysm volume</measure>
    <time_frame>36 months</time_frame>
    <description>difference of aneurysm volume (in computerized measurements defined as increase of aneurysm volume in computerized measurements by &gt;10% and &gt;3mm3 or aneurysm shape (e.g. development of daughter sac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new aneurysm</measure>
    <time_frame>36 months</time_frame>
    <description>development of de novo aneurysm on serial imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>therapy of aneurysm</measure>
    <time_frame>36 months</time_frame>
    <description>clipping/coiling during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>36 months</time_frame>
    <description>any ischemic or haemorrhagic stroke, defined as clinical symptoms for stroke AND a compatible lesion on imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocard infarction</measure>
    <time_frame>36 months</time_frame>
    <description>myocardial infarction defined as increase of troponin, creatine-kinase MB and/or presence of new significant Q waves obtained in electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular death</measure>
    <time_frame>36 months</time_frame>
    <description>vascular death (including fatal stroke, fatal myocardial infarction, sudden death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>36 months</time_frame>
    <description>major spontaneous bleeding requiring hospitalisation defined as substantially disabling bleeding, intraocular bleeding leading to the loss of vision, or bleeding necessitating the transfusion of at least 2 units of erythrocyte concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>36 months</time_frame>
    <description>death from all other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>achieved blood pressure</measure>
    <time_frame>36 months</time_frame>
    <description>any data on blood pressure management used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse and Serious Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>all adverse and serious adverse events related to the experimental intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">776</enrollment>
  <condition>Unruptured Intracranial Aneurysms</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blood pressure management according to guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>100 mg daily as one tablet</description>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intensive blood pressure control</intervention_name>
    <description>Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.</description>
    <arm_group_label>Acetylsalicylic acid, BP-target 120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older with an intradural, saccular unruptured aneurysm (UIA) in
             whom it is decided not to intervene with preventive endovascular or neurosurgical
             repair of the aneurysm and who are monitored on a regular base for aneurysm growth

          -  Last aneurysm imaging with either CTA/MRA/DSA within the last 3 months

        Exclusion Criteria:

          -  All non-saccular UIAs or aneurysms related to arteriovenous malformations

          -  Frequent ASA use and/or indication for a vitamin K antagonist, or direct oral
             anticoagulant (DOAC) treatment at baseline

          -  Contra-indication for ASA

          -  History of hypersensitivity to ASA or to any other drug with similar chemical
             structure or to any excipient present in the pharmaceutical form of ASA

          -  Chronic kidney disease stage IV and V (GFR &lt; 30 mL/min/1.73 m2)

          -  Pregnancy and lactation

          -  Participation in another clinical trial or observation period of competing trials,
             respectively

          -  Life-expectancy &lt;3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nima Etminan, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMM, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mervyn D Vergouwen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht, Department of Neurology and Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nima Etminan, PD Dr. med.</last_name>
    <phone>+49 621 383-2360</phone>
    <email>Nima.Etminan@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mervyn DI Vergouwen, M.D., Ph.D.</last_name>
    <phone>+31 88 75 50455</phone>
    <email>M.D.I.Vergouwen@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology and Neurosurgery, Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmuth Steinmetz, Prof. Dr.</last_name>
      <phone>+49 69 6301-5769</phone>
      <email>helmuth.steinmetz@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Konczalla, PD Dr</last_name>
      <email>J.Konczalla@med.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmuth Steinmetz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nima Etminan, PD Dr. med.</last_name>
      <phone>+49-621-383-2360</phone>
      <email>nima.etminan@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Hackenberg, Dr.med.</last_name>
      <phone>+49-621-383-2360</phone>
      <email>katharina.hackenberg@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nima Etminan, PD Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Haenggi, Prof. Dr.med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Nima Etminan</investigator_full_name>
    <investigator_title>Vice Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

